|
ABC-07 |
Addition of stereotactic radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers |
Dr Thankamma Ajithkumar |
31 Aug 2023 |
5 Apr 2017 |
Liver & Bile Duct |
|
Add-Aspirin Trial |
A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours |
Dr Luke Hughes-Davies |
11 Dec 2020 |
21 Dec 2015 |
Breast, Colorectal, Oesophageal, Prostate |
|
ADSCaN |
A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-small Cell Lung Cancer |
Dr Susan Harden |
31 Dec 2021 |
23 Nov 2017 |
Lung |
|
ALF Research Study |
Research into Altered Lymphocyte Function in Health and Disease |
Dr Kate Fife |
31 Dec 2022 |
9 Nov 2017 |
Skin & melanoma |
|
AML 18 |
A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome |
Dr Jenny Craig |
31 Dec 2020 |
7 Dec 2015 |
Haematological |
|
AML 19 |
Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome |
Dr Jenny Craig |
9 Nov 2021 |
15 Oct 2015 |
Haematological |
|
Ariel 4 (CANC 5651) |
A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Dr James Brenton |
11 Apr 2020 |
11 Apr 2017 |
Gynaecological |
|
Artist 1 |
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen |
Dr Pippa Corrie |
30 Dec 2019 |
21 Jul 2017 |
Pancreatic |
|
Athena |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy |
Dr Christine Parkinson |
31 Mar 2023 |
27 Mar 2019 |
Gynaecological |
|
BMS Retrospective RCC Study |
Estimating health outcomes in patients with advanced or Metastatic Renal Cell Carcinoma (mRCC) treated with systemic therapy, using real-world data - CA209671 |
Dr Kate Fife |
30 Jul 2021 |
22 Mar 2017 |
Kidney |
|
BRITER |
Brain Imaging to predict Toxicity in Elderly patients after Radiotherapy |
Dr Gary Doherty |
31 Mar 2021 |
10 Jan 2019 |
Brain and CNS |
|
Cabozantinib in patients with advanced renal cell carcinoma |
a non-interventional retrospective study to describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma in the uk |
Dr Kate Fife |
18 Dec 2020 |
18 Dec 2018 |
Kidney |
|
Cambridge Prostate Biopsy Device: CAMPROBE |
Developing a safer and more accurate device for biopsies of suspected cancer |
Mr Vincent Gnanapragasam |
30 Sep 2019 |
2 Feb 2016 |
Prostate |
|
Cervical Cell Lift |
Collection of Cervical Cells at Colposcopy using a novel technique for analysis of high risk vs. low risk lesions |
Dr Robin Crawford |
31 Dec 2020 |
14 Jul 2017 |
Gynaecological |
|
COMBI-Aplus |
Open-label, phase IIIb study of dabrafenib in combination with trametinib in the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE-management algorithm |
Dr Pippa Corrie |
31 Jul 2019 |
7 Sep 2018 |
Skin & melanoma |
|
CompARE Trial |
Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer |
Dr Rashmi Jadon |
31 Jan 2026 |
5 Mar 2019 |
Head & neck |
|
Dante |
A randomised phase III trial to evaluate the duration of anti-PD1 monoclonal antibody treatment in patients with metastatic melanoma |
Dr Pippa Corrie |
31 Mar 2023 |
21 Sep 2018 |
Skin & melanoma |
|
Developing and validation SAM |
Study to develop and validate a sarcoma-specific outcome questionnaire: the Sarcoma Assessment Measure (SAM): , PHASE 2 |
Dr Helen Hatcher |
31 May 2019 |
18 Mar 2019 |
Sarcoma |
|
DIG (Diffusion imaging in gliomas) |
Quantitative diffusion imaging for early treatment response and progression evaluation in adult high grade gliomas; a multicentre study |
Dr Tomasz Matys |
31 Dec 2019 |
13 Jul 2018 |
Brain and CNS |
|
EMBRACE-II |
Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer |
Dr Li Tee Tan |
30 Jun 2024 |
7 Nov 2017 |
Gynaecological |
|
Euro Ewing 2012 |
International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours |
Dr Denise Williams |
31 May 2019 |
30 Apr 2015 |
Sarcoma |
|
EuroNet-PHL-C2 |
Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents |
Dr Ben Uttenthal |
30 Sep 2021 |
30 Oct 2018 |
Haematological |
|
FAST-Forward |
FAST Forward is a randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in patients with early breast cancer.
The lymphatic RT sub-study an extension to the FAST-Forward trial, which maintains its original design but whose entry is now restricted to patients prescribed radiotherapy to level I-III axilla and/or level IV axilla (supraclavicular fossa (SCF)) in addition to the breast/chest wall area.
|
Dr Charlotte Coles |
1 Feb 2022 |
12 Mar 2012 |
Breast |
|
FLAIR |
Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab |
Dr George Follows |
4 Feb 2020 |
19 Jan 2015 |
Haematological |
|
FOCUS 4 |
FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme |
Dr Hugo Ford |
25 Nov 2020 |
1 Dec 2015 |
Colorectal |
|
GLOW |
A Randomized, Open-label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
Dr George Follows |
30 Apr 2019 |
28 Jun 2018 |
Haematological |
|
GO39942 (Polarix) |
A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma (DLBCL) |
Dr George Follows |
30 Oct 2019 |
16 Nov 2018 |
Haematological |
|
Gravitas |
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease |
Dr Pramila Krishnamurthy |
31 Jan 2020 |
30 May 2018 |
Haematological |
|
HGUSStudy |
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment |
Dr Helen Hatcher |
30 Dec 2019 |
11 Mar 2016 |
Sarcoma |
|
ICON8B |
A phase III randomised trial investigating the combination of dose-fractionated chemotherapy & bevacizumab compared to either strategy alone for the first line treatment of women with newly diagnosed high risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer |
Dr Christine Parkinson |
31 Jul 2019 |
8 Feb 2012 |
Gynaecological |
|
INTERIM |
a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma |
Dr Pippa Corrie |
30 Apr 2019 |
3 Nov 2017 |
Skin & melanoma |
|
IoN |
IoN Is ablative radio-iodine necessary for low risk differentiated thyroid cancer patients |
Dr Sarah Jefferies |
31 Dec 2019 |
28 Nov 2012 |
Head & neck |
|
IpiGlio |
A Phase II, open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma |
Dr Fiona Harris |
31 Jul 2020 |
21 Jan 2019 |
Brain and CNS |
|
Keynote 775 |
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer |
Dr Christine Parkinson |
17 Oct 2020 |
17 Oct 2018 |
Gynaecological |
|
LI-1 |
Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial |
Dr Jenny Craig |
31 Dec 2019 |
17 Feb 2014 |
Haematological |
|
MDS AZA 003 |
A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to IPSS lower-risk myelodysplatic syndromes |
Dr Theodora Foukaneli |
30 Oct 2020 |
27 Oct 2014 |
Haematological |
|
MDS Registry for newly diagnosed patients |
A prospective, multicentre European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes |
Professor Alan Warren |
1 May 2020 |
16 Feb 2009 |
Haematological |
|
MDV3800-06 |
A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) |
Dr Danish Mazhar |
30 Apr 2019 |
18 Oct 2017 |
Prostate |
|
MEASURES |
The MPN Experimental Assessment of Symptoms by Utilizing Repetitive Evaluation (MEASURES) |
Dr Anna Godfrey |
31 Dec 2020 |
12 Jul 2017 |
Haematological |
|
Mediola |
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors |
Dr Christine Parkinson |
18 Oct 2020 |
18 Oct 2018 |
Gynaecological |
|
Minitub Registration Study (EORTC 1208) |
Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissection (CLND) or Nodal Observation |
Dr Amer Durrani |
1 May 2021 |
19 Oct 2017 |
Skin & melanoma |
|
MK3475-716 |
Adjuvant therapy with pembrolizumab versus placebo in resected stage II melanoma: a randomized, double-blind phase III study |
Dr Pippa Corrie |
31 Jul 2020 |
25 Oct 2018 |
Skin & melanoma |
|
MyeChild 01 |
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy |
Dr Michael Gattens |
1 Nov 2021 |
31 Oct 2016 |
Haematological |
|
Myeloma XII |
A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem |
Dr Charles Crawley |
31 Dec 2021 |
22 May 2017 |
Haematological |
|
National Lung Matrix Trial |
Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer |
Dr David Gilligan |
31 Dec 2020 |
17 Nov 2015 |
Lung |
|
NAXIVA |
Phase II Neoadjuvant study of AXItinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with Venous invAsion |
Dr Grant Stewart |
30 Sep 2019 |
4 Dec 2017 |
Kidney |
|
Neo-AEGIS |
Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (MAGIC regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction |
Dr Hugo Ford |
1 Sep 2020 |
24 Nov 2015 |
Oesophageal |
|
OPTIMA |
Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis |
Dr Luke Hughes-Davies |
31 Oct 2020 |
25 Oct 2012 |
Breast |
|
PARADIGM Phase II |
Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study |
Dr Sarah Jefferies |
30 Apr 2020 |
4 Nov 2016 |
Brain and CNS |
|
PARTNER |
Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA |
Dr Jean Abraham |
31 Mar 2021 |
12 May 2016 |
Breast |
|
PEACE |
The PEACE (Posthumous tissuE donAtion in CancEr) Study |
Dr James Brenton |
8 Oct 2020 |
8 Oct 2018 |
Gynaecological, Breast |
|
Pharmacyclics PCYC 1141 (Bruton's Tyrosine Kinase Inhibitor, Treatment for Follicular Lymphoma) |
A Multicentre, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma |
Dr George Follows |
31 May 2019 |
27 Jul 2018 |
Haematological |
|
PHAZAR |
A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase MyeloproliferatIve neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN. |
Dr Anna Godfrey |
31 Dec 2019 |
12 Jun 2018 |
Haematological |
|
PIANO Study PLX3397 |
A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma |
Dr Christine Parkinson |
31 Dec 2019 |
4 Apr 2016 |
Skin & melanoma |
|
PIVOTALboost |
A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost. |
Dr Yvonne Rimmer |
17 Aug 2020 |
7 Mar 2018 |
Prostate |
|
plasmaMATCH |
A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening |
Dr Richard Baird |
31 Dec 2020 |
11 Apr 2017 |
Breast |
|
PLATO |
PersonaLising Anal cancer radioTherapy dOse |
Dr Catherine Jephcott |
31 Dec 2022 |
22 Mar 2017 |
Colorectal |
|
POPS |
A randomised phase II trial assessing Post-Operative use of ProSpare, a rectal obturator in prostate cancer radiotherapy |
Dr Yvonne Rimmer |
31 Dec 2019 |
4 Jul 2017 |
Prostate |
|
PRaM-GBM |
Predicting sites of tumour progression in the invasive margin of glioblastomas |
Mr Stephen Price |
31 Dec 2019 |
1 Feb 2017 |
Brain and CNS |
|
PRECISION-Panc |
Advancing personalised medicine treatment strategies for pancreatic cancer |
Dr Bristi Basu |
29 Aug 2019 |
25 Apr 2018 |
Pancreatic |
|
PRIMETIME |
Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers |
Dr Charlotte Coles |
31 Dec 2021 |
18 May 2017 |
Breast |
|
PRIMUS-001 |
An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation |
Dr Pippa Corrie |
30 Aug 2019 |
10 May 2018 |
Pancreatic |
|
PRISM |
A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma |
Dr Kate Fife |
31 Dec 2019 |
6 Jun 2018 |
Kidney |
|
Quality of Life After Bladder Cancer (Q-ABC) |
A comparison of patient related outcomes following radical surgery and radiotherapy |
Dr Yvonne Rimmer |
1 Mar 2022 |
23 Oct 2018 |
Bladder |
|
RAIDER |
A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder |
Dr Yvonne Rimmer |
21 Mar 2029 |
6 Jan 2016 |
Bladder |
|
RAMPART |
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised-controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse |
Dr Sarah Welsh |
31 Dec 2023 |
20 Jul 2018 |
Kidney |
|
rEECur |
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma |
Dr Denise Williams |
30 Apr 2020 |
5 May 2016 |
Sarcoma |
|
RENA 4970 (The Water Study) |
Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue |
Mr Tevita Aho |
30 Nov 2019 |
4 Feb 2016 |
Prostate |
|
SARON |
Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial |
Dr Susan Harden |
4 Jul 2023 |
9 Aug 2017 |
Lung |
|
SEAL |
A Phase 2-3, multicenter, randomized, doubleblind study of selinexor (KPT-330) versus placebo in patients with advanced unresectable dedifferentiated liposarcoma (DDLS) |
Dr James Robin |
31 Aug 2019 |
7 Nov 2018 |
Sarcoma |
|
SHAPE |
A randomized phase III trial comparing radical hysterectomy and pelvic node dissection versus simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer |
Mr Robin Crawford |
11 Jan 2020 |
11 Jan 2016 |
Gynaecological |
|
SMS Study |
Study of Somatic Sutations using genome Sequencing |
Dr Philip Jones |
1 Aug 2019 |
18 Oct 2015 |
Skin & melanoma |
|
SPECTA (EORTC 1553) |
Screening cancer patients for efficient clinical trial access |
Dr Helen Hatcher |
31 Dec 2021 |
1 Aug 2018 |
Sarcoma |
|
SSGXXII |
Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study |
Dr Ramesh Bulusu |
31 Dec 2020 |
1 Mar 2017 |
Sarcoma |
|
STAMPEDE |
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy |
Dr Danish Mazhar |
6 Sep 2020 |
1 Aug 2018 |
Prostate |
|
TAMARIN |
Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloproliferatIve Neoplasms |
Dr Anna Godfrey |
31 Dec 2019 |
14 Dec 2016 |
Haematological |
|
Target Fal01 |
Translational Analysis and Research in Gynaecological Epithelial Tissues - Fallopian Tubes |
Dr Filipe Correia Martins |
30 Nov 2021 |
11 Jan 2019 |
Gynaecological |
|
The Causes of Clonal Blood Cell Disorders |
The Causes of Clonal Blood Cell Disorders |
Professor Tony Green |
31 Dec 2019 |
1 Jan 2008 |
Haematological |
|
UK P3BEP Trial |
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours |
Dr Danish Mazhar |
30 Jun 2020 |
5 May 2017 |
Testicular |
|
UKALL 14 |
A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia |
Dr Jenny Craig |
31 Dec 2019 |
31 Jul 2012 |
Haematological |
|
UTX-TGR-205 (Unity NHL) |
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma. |
Dr Dan Hodson |
29 Dec 2020 |
29 Dec 2017 |
Haematological |
